Pharmafile Logo
Pharmafocus logo
Advanced Search

avastin

Showing 15 posts of 94 posts found.

Avastin

Roche gains new licence for blockbuster oncology drug

August 6, 2014
Research and Development, Sales and Marketing EC, Roche, avastin, ovarian cancer

Roche’s blockbuster cancer treatment Avastin now has a new European licence to treat women with a certain type of ovarian …

News
roche_logo_shadow_7

FDA speedy review for new Avastin licence

July 16, 2014
Research and Development, Sales and Marketing Cancer, Roche, avastin, cervical cancer

The FDA has granted priority review status for Roche’s Avastin (bevacizumab) plus chemotherapy in women with persistent, recurrent or metastatic …

News

France ‘to approve’ Avastin use

July 3, 2014
Sales and Marketing AMD, France, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

The French government is planning to allow Roche’s cancer drug Avastin to be prescribed off-label to treat wet age-related macular …

News

Novartis back under microscope

June 23, 2014
Medical Communications, Sales and Marketing Italy, Novartis, avastin, fraud, influenza, vaccines

Novartis is under the microscope yet again in Italy, with police visiting the company’s sites at Siena and Origgio in …

News

Italy eyes €1.2 billion pharma fine

May 30, 2014
Sales and Marketing Novartis, Roche, avastin, off label, wet and

Italy’s health ministry says it is looking for €1.2 billion in damages from Roche and Novartis over claims that the …

News
Avastin image

EU looks at eye drug allegations

May 8, 2014
Sales and Marketing EU, Lucentis, Novartis, Roche, avastin, offlabel

European Union regulators are considering whether they need to take any action over the recent allegations of anti-competitiveness involving Roche …

News
roche_logo_shadow

Roche/Novartis offices raided over anti-competitive activities

April 11, 2014
Sales and Marketing Lucentis, Novartis, Roche, SHIP Cluster, avastin, wet AMD

French competition authorities are investigating Roche and Novartis in connection with their marketing of Lucentis for wet age-related macular degeneration …

News
Supercomputer image

IBM supercomputer could hold key to brain cancer

March 21, 2014
Medical Communications, Sales and Marketing avastin, brain cancer, ibm, nygc, supercomputer

The New York Genome Center and IBM Watson have joined forces to accelerate a new era of genomic medicine, initially …

News
roche_logo_shadow

Roche lung cancer drug fails

March 3, 2014
Research and Development, Sales and Marketing Cancer, MetMAb, NSCLC, Roche, Tarceva, avastin

An independent data monitoring committee has told Roche to halt a study of its experimental lung cancer drug MetMab due …

News
Lisa image

A treatment room view

February 24, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer, NHS, NICE, Roche, avastin, hinsely

A little more than a year ago, Lisa Hinsley’s prospects were not good. The mother of three had been diagnosed …

Feature
Avastin packshot

UK pharma teams up for better cancer drug access

September 20, 2013
Medical Communications, Sales and Marketing Cancer Drugs Fund, NICE, Novartis, Roche, Sanofi, avastin, no

News
Lucentis image

Lucentis and Avastin equal in efficacy

July 19, 2013
Research and Development, Sales and Marketing Lucentis, Novartis, Roche, avastin

Latest results released this morning from a UK government trial show that off-label use of Roche’s Avastin is just as …

News
Avastin image

Avastin gets GBM approval

June 18, 2013
Research and Development, Sales and Marketing GBM, Roche, avastin

Roche has received a major boost with the first approval in early treatment of the most aggressive form of brain …

News
Eylea image

Eylea approval for wet AMD

November 29, 2012
Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD

Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …

News
Avastin image

Avastin shows brain cancer benefit

November 20, 2012
Research and Development, Sales and Marketing Cancer, FDA, Merck, Roche, avastin, brain

In a Phase III trial, Roche’s Avastin has helped people with newly-diagnosed glioblastoma (GBM) live longer without their disease worsening. …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024